RxDoctor Payments Data

Tiffany Roe, APRN

Family · Shreveport, LANPI 1548661440

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Lilly USA, LLC at 42.0% of the total. Reporting peaked in 2022 at $30,944 and has fallen 69.2% since, to $9,537 in 2025. Among family clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$97,029in general payments, 2019–2025

Across 1,118 payments — averaging $86.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$41K
  • AbbVie$22K
  • Amgen$15K
  • Novartis$4K
  • Johnson & Johnson$3K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $10K from 23 others

What the payments were for

  • Consulting fees$11,46812%
  • Speaking & faculty fees$56,11358%
  • Travel & lodging$6,7097%
  • Food & beverage$22,62223%
  • Education$1180%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$97,029 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,857
Medicare patients
107
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MethotrexateMethotrexate Sodium533$14,815
Hydroxychloroquine Sulfate298$12,839
Leflunomide98$7,836
Celecoxib100$3,140
Leucovorin Calcium50$2,128
Allopurinol135$1,601
Mycophenolate Mofetil21$1,315
Diclofenac Sodium11$758
Sulfasalazine31$637
Folic Acid48$545
Methotrexate SodiumMethotrexate Sodium/Pf11$210
Prednisone20$131
Alendronate Sodium26$89

Paid to pharmacies, not to this prescriber.

Other family in Shreveport

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →